A Phase 3 interventional study of Ruxolitinib Cream and Vehicle Cream in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 79 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one has the largest enrollment, is one of 2 that started in 2018, is one of 6 in phase 3, and was the 3rd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 2+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 631 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 77 across the 15 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 3 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
17 studies in Dermatitis, Atopic by Incyte Corporation: 2 open now, 3 under way, 1 of them phase 3. Of 14 finished, 10 (71%) have results posted.
Among the 17 studies in Dermatitis, Atopic by Incyte Corporation, this one has the largest enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2018, is one of 6 in phase 3, and was the 3rd registered.
Incyte Corporation’s Dermatitis, Atopic studies by the year they started, since 2017.
1 of the studies testing ruxolitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07661979Wake Forest University Health SciencesOpzelura Experience Study | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Incyte Corporation’s 17 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Concurrent conditions and history of other diseases:
Use of any of the following treatments within the indicated before Baseline:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the Vehicle Control (VC) Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
Drug: Vehicle Cream
Participants received ruxolitinib 0.75% cream, applied topically to the affected areas as a thin film BID from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
Drug: Ruxolitinib Cream
Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film BID from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
Drug: Ruxolitinib Cream
Participants who applied vehicle cream BID during the VC Period, were randomized to apply ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID from Week 8 to 52 during the Long-term Safety (LTS) Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
Drug: Ruxolitinib Cream
Participants who applied vehicle cream BID during the VC Period, were randomized to apply ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
Drug: Ruxolitinib Cream
Arm description: Participants who applied ruxolitinib 0.75% cream during VC Period, continued applying ruxolitinib 0.75% cream topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
Drug: Ruxolitinib Cream
Arm description: Participants who applied ruxolitinib 1.5% cream during VC Period, continued applying ruxolitinib 1.5% cream topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
Drug: Ruxolitinib Cream
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Also known as: INCB018424 Phosphate Cream
Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8
The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.
Time frame: Baseline to Week 8
VC Period: Percentage of Participants Who Achieved Eczema Area and Severity Index 75 (EASI75)
EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.
Time frame: Baseline to Week 8
VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch Numerical Rating Scale (NRS) Score
The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants were asked to rate the itching severity because of their AD in the daily diary by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best described their worst level of itching in the past 24 hours.
Time frame: Baseline to Week 8
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep Disturbance (8b - 24-Hour Recall) Score
The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. Each item asks the participant to rate the severity of the participant's sleep disturbance.
Time frame: Baseline to Week 8
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall)
The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. Each item asks the participant to rate the severity of the participant's sleep impairment.
Time frame: Baseline to Week 8
VC Period: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (SAE)
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.
Time frame: From first dose up to Week 8
LTS Period: Percentage of Participants With at Least One TEAE and Treatment Emergent SAE
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.
Time frame: From first dose date in LTS Period (Week 8) until last follow-up visit (up to 52 weeks)
VC Period: Percentage of Participants Who Achieved an IGA-TS at Weeks 2 and 4
The IGA is an overall eczema severity rating on a 0 (clear skin) to 4 (severe disease) scale. The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.
Time frame: Baseline to Weeks 2 and 4
VC Period: Percentage of Participants Achieving IGA Scores of 0 or 1
The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. IGA score signifies 0 (clear skin) and 1 (almost clear skin).
Time frame: Weeks 2, 4 and 8
LTS Period: Percentage of Participants Achieving IGA Scores of 0 or 1
The IGA is an overall eczema severity rating on a 0 (clear skin) to 4 (severe disease) scale. The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. IGA score signifies 0 (clear skin) and 1 (almost clear skin).
Time frame: Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch NRS Score From Baseline to Weeks 2 and 4
The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours.
Time frame: Baseline to Weeks 2 and 4
VC Period: Percentage of Participants Achieving EASI50
EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI50 responder was defined as a participant achieving 50% or greater improvement from Baseline in EASI score.
Time frame: Weeks 2, 4 and 8
VC Period: Percentage of Participants Achieving EASI75
EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.
Time frame: Weeks 2 and 4
VC Period: Percentage of Participants Achieving EASI90
EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI90 responder was defined as a participant achieving 90% or greater improvement from Baseline in EASI score.
Time frame: Weeks 2, 4 and 8
VC Period: Percent Change From Baseline in EASI Score
EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4 and 8
VC Period: Percent Change From Baseline In SCORing Atopic Dermatitis (SCORAD) Score
The SCORAD is a tool to assess extent and severity of eczema. To determine the extent, the rule of nines or handprint method is used to assess eczema affected area (A). To determine disease severity (B) it evaluates 6 clinical characteristics: 1. redness, 2. swelling, 3. oozing/crusting, 4. scratch marks, 5. lichenification, and 6. dryness on a 4-point scale of 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), added to give B with maximum score of 18. Subjective symptoms (C) of itch and sleeplessness are assessed using a visual analogue scale where 0 is no itch (or no sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), added to give C with maximum score of 20. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combined using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4 and 8
VC Period: Change From Baseline in Itch NRS Score
The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4, and 8
VC Period: Time to Achieve Itch NRS Score Improvement of at Least 2, 3, or 4 Points
The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants were asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. Kaplan-Meier estimation method was used for analyses.
Time frame: Up to Week 8
VC Period: Change From Baseline in Skin Pain NRS Score
The Skin Pain NRS is a daily patient-reported measure (24-hour recall), using a diary, of the worst level of pain intensity from 0 (no pain) to 10 (worst imaginable pain). Participants will be asked, "Rate the pain severity from your atopic dermatitis skin changes by selecting a number that best describes your worst level of pain in the past 24 hours." A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4, and 8
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score
The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance.
Time frame: Weeks 2 and 4
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score
The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment.
Time frame: Weeks 2 and 4
VC Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score
The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4, and 8
VC Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score
The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4, and 8
LTS Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 7-Day Recall Score
The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 12, 24, and 52
LTS Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 7-Day Recall Score
The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 12, 24, and 52
VC Period: Change From Baseline in Atopic Dermatitis Afflicted Percentage of Body Surface Area (%BSA)
Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Used the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4 and 8
LTS Period: Change From Baseline in Atopic Dermatitis Afflicted %BSA
Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Used the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
VC Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score
The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (clear or almost clear) to 28 (very severe eczema). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4, and 8
LTS Period: Change From Baseline in POEM Score
The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 12, 24, and 52
VC Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Score
The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.
Time frame: Baseline, Weeks 2, 4, and 8
LTS Period: Change From Baseline in DLQI Score
The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.
Time frame: Baseline, Weeks 12, 24, and 52
VC Period: Change From Baseline in Children Dermatology Life Quality Index (CDLQI) Score
CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.
Time frame: Baseline, Weeks 2, 4, and 8
LTS Period: Change From Baseline in CDLQI Score
CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.
Time frame: Baseline, Weeks 12, 24, and 52
VC Period: Mean Patient Global Impression of Change (PGIC) Score at Weeks 2, 4, and 8
The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.
Time frame: Weeks 2, 4, and 8
VC Period: Percentage of Participants With Each Score on the PGIC at Weeks 2, 4, and 8
The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.
Time frame: Weeks 2, 4, and 8
VC Period: Percentage of Participants With a Score of Either 1 or 2 on the PGIC at Weeks 2, 4, and 8
The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.
Time frame: Weeks 2, 4, and 8
VC Period: Change From Baseline in EuroQuality of Life Five Dimensions (EQ-5D-5L) Visual Analogue Scale (VAS) Score
EQ-5D-5L questionnaire has 2 parts: EQ-5D-5L descriptive system \& EQ-VAS. EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 5L indicates that for each dimension, there are 5 levels:1=no problems,2=slight problems,3=moderate problems,4=severe problems, and 5=extreme problems. EQ-5D-5L score is assessed using VAS that ranges from 0 to 100 millimetres (mm), where 0 indicates "worst health you can imagine" and 100 indicates "best health you can imagine". The participant was asked to indicate his/her health state over past 7 days in each of the 5 dimensions. Digits for the 5 dimensions can be combined into a 5-digit number that describes the participant's health state. In the EQ-VAS, participants had to record their health state on a scale ranging from 0 to 100. A positive change from Baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4, and 8
VC Period: Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) Version 2.0 (v2.0)
The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4, and 8
LTS Period: Change From Baseline in WPAI-SHP v2.0
The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.
Time frame: Baseline, Weeks 12, 24, 36, and 52
VC Period: Trough Plasma Concentrations of Ruxolitinib
Plasma samples were collected just before the morning application of study drug during each specified time point.
Time frame: Pre-dose at Weeks 2, 4 and 8
LTS Period: Trough Plasma Concentrations of Ruxolitinib
Plasma samples were collected just before the morning application of study drug during each specified time point.
Time frame: Pre-dose at Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
A total of 631 participants took part in the study at 78 sites, 48 in North America and 30 in Europe from December 20, 2018 to December 01, 2020.
| Milestone | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|---|---|---|
| Started | 126 | 252 | 253 | 0 | 0 | 0 | 0 |
| Completed | 95 | 222 | 225 | 0 | 0 | 0 | 0 |
| Not completed | 31 | 30 | 28 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 12 | 8 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 17 | 11 | 19 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 48 | 47 | 222 | 225 |
| Completed | 0 | 0 | 0 | 37 | 38 | 176 | 174 |
| Not completed | 0 | 0 | 0 | 11 | 9 | 46 | 51 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 6 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 3 | 5 | 13 | 24 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 7 | 3 | 17 | 21 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 4 | 3 |
The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 | 15.1 (9.3 to 22.5) | 50.0 (43.7 to 56.3) | 53.8 (47.4 to 60.0) |
EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| VC Period: Percentage of Participants Who Achieved Eczema Area and Severity Index 75 (EASI75) | 24.6 (17.4 to 33.1) | 56.0 (49.6 to 62.2) | 62.1 (55.8 to 68.1) |
The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants were asked to rate the itching severity because of their AD in the daily diary by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best described their worst level of itching in the past 24 hours.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch Numerical Rating Scale (NRS) Score | 15.4 | 40.4 | 52.2 |
The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. Each item asks the participant to rate the severity of the participant's sleep disturbance.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep Disturbance (8b - 24-Hour Recall) Score | 9.5 | 21.0 | 22.3 |
The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. Each item asks the participant to rate the severity of the participant's sleep impairment.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall) | 13.2 | 20.2 | 21.6 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| TEAE | 34.9 | 29.0 | 29.2 |
| Treatment Emergent SAE | 1.6 | 0.4 | 0.8 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.
| percentage of participants | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| TEAE | 47.9 | 48.9 | 54.5 | 53.3 |
| Treatment Emergent SAE | 6.3 | 2.1 | 2.3 | 1.3 |
The IGA is an overall eczema severity rating on a 0 (clear skin) to 4 (severe disease) scale. The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Week 2 | 3.2 | 22.2 | 27.3 |
| Week 4 | 6.3 | 42.5 | 46.6 |
The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. IGA score signifies 0 (clear skin) and 1 (almost clear skin).
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Week 2 | 6.3 | 32.5 | 34.8 |
| Week 4 | 15.1 | 53.2 | 54.9 |
| Week 8 | 23.8 | 58.7 | 62.8 |
The IGA is an overall eczema severity rating on a 0 (clear skin) to 4 (severe disease) scale. The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. IGA score signifies 0 (clear skin) and 1 (almost clear skin).
| percentage of participants | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Week 8 | 18.8 | 38.3 | 65.3 | 68.4 |
| Week 12 | 55.6 | 65.2 | 62.7 | 66.5 |
| Week 16 | 60.5 | 62.2 | 66.5 | 68.9 |
| Week 20 | 63.6 | 67.4 | 62.4 | 73.5 |
| Week 24 | 71.4 | 78.6 | 67.0 | 76.7 |
| Week 28 | 64.9 | 74.4 | 67.3 | 77.3 |
| Week 32 | 77.1 | 81.4 | 71.5 | 75.9 |
| Week 36 | 73.5 | 82.1 | 74.5 | 71.7 |
| Week 40 | 81.3 | 79.5 | 73.5 | 75.5 |
| Week 44 | 84.8 | 86.5 | 74.3 | 76.2 |
| Week 48 | 72.2 | 76.3 | 74.3 | 73.8 |
| Week 52 | 76.3 | 73.7 | 76.9 | 75.4 |
The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Week 2 | 5.1 | 26.3 | 33.5 |
| Week 4 | 11.5 | 38.5 | 51.6 |
EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI50 responder was defined as a participant achieving 50% or greater improvement from Baseline in EASI score.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Week 2 | 19.8 | 53.2 | 62.5 |
| Week 4 | 27.8 | 68.7 | 75.5 |
| Week 8 | 43.7 | 69.4 | 77.9 |
EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Week 2 | 5.6 | 30.2 | 36.0 |
| Week 4 | 14.3 | 51.6 | 58.5 |
EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI90 responder was defined as a participant achieving 90% or greater improvement from Baseline in EASI score.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Week 2 | 2.4 | 12.7 | 19.8 |
| Week 4 | 4.0 | 30.6 | 36.4 |
| Week 8 | 9.5 | 38.1 | 44.3 |
EASI scoring system examines 4 areas of the body and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree of severity of each sign in each region. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. A negative change from Baseline indicates improvement.
| percent change | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Percent Change From Baseline at Week 2 | -16.34 ± 3.42 | -51.82 ± 2.36 | -56.62 ± 2.35 |
| Percent Change From Baseline at Week 4 | -23.03 ± 3.90 | -68.04 ± 2.66 | -71.08 ± 2.64 |
| Percent Change From Baseline at Week 8 | -37.88 ± 3.72 | -71.01 ± 2.52 | -77.40 ± 2.49 |
The SCORAD is a tool to assess extent and severity of eczema. To determine the extent, the rule of nines or handprint method is used to assess eczema affected area (A). To determine disease severity (B) it evaluates 6 clinical characteristics: 1. redness, 2. swelling, 3. oozing/crusting, 4. scratch marks, 5. lichenification, and 6. dryness on a 4-point scale of 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), added to give B with maximum score of 18. Subjective symptoms (C) of itch and sleeplessness are assessed using a visual analogue scale where 0 is no itch (or no sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), added to give C with maximum score of 20. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combined using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. A negative change from Baseline indicates improvement.
| percent change | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Percent Change From Baseline at Week 2 | -16.67 ± 34.152 | -43.96 ± 28.548 | -49.32 ± 31.878 |
| Percent Change From Baseline at Week 4 | -27.68 ± 34.518 | -57.80 ± 28.635 | -61.33 ± 30.113 |
| Percent Change From Baseline at Week 8 | -37.00 ± 36.392 | -62.14 ± 31.108 | -67.24 ± 28.711 |
The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. A negative change from Baseline indicates improvement.
| score on a scale | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Change From Baseline at Week 2 | -0.89 ± 0.20 | -2.28 ± 0.14 | -2.53 ± 0.13 |
| Change From Baseline at Week 4 | -1.08 ± 0.23 | -2.79 ± 0.16 | -3.16 ± 0.15 |
| Change From Baseline at Week 8 | -1.54 ± 0.25 | -3.14 ± 0.17 | -3.53 ± 0.16 |
The Itch NRS is a daily participant-reported measure (24-hour recall), using a diary, of the worst level of itch intensity. Participants were asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. Kaplan-Meier estimation method was used for analyses.
| days | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| ≥ 2-Point Improvement in Itch NRS Score | 15.0 (10.0 to 22.0) | 4.0 (3.0 to 5.0) | 3.0 (3.0 to 4.0) |
| ≥ 3-Point Improvement in Itch NRS Score | 27.0 (13.0 to 69.0) | 8.0 (7.0 to 11.0) | 6.0 (5.0 to 9.0) |
| ≥ 4-Point Improvement in Itch NRS Score | NA (28.0 to NA) | 14.0 (9.0 to 19.0) | 13.0 (9.0 to 15.0) |
The Skin Pain NRS is a daily patient-reported measure (24-hour recall), using a diary, of the worst level of pain intensity from 0 (no pain) to 10 (worst imaginable pain). Participants will be asked, "Rate the pain severity from your atopic dermatitis skin changes by selecting a number that best describes your worst level of pain in the past 24 hours." A negative change from Baseline indicates improvement.
| score on a scale | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Change From Baseline at Week 2 | -0.70 ± 1.746 | -1.90 ± 1.950 | -2.07 ± 2.164 |
| Change From Baseline at Week 4 | -0.84 ± 2.307 | -2.36 ± 2.217 | -2.72 ± 2.513 |
| Change From Baseline at Week 8 | -1.16 ± 2.610 | -2.55 ± 2.360 | -2.84 ± 2.743 |
The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Week 2 | 5.2 | 13.7 | 14.7 |
| Week 4 | 6.9 | 19.3 | 21.0 |
The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Week 2 | 8.8 | 16.3 | 13.5 |
| Week 4 | 13.2 | 20.6 | 19.2 |
The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.
| score on a scale | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Change From Baseline at Week 2 | -0.18 ± 0.45 | -1.72 ± 0.31 | -2.49 ± 0.30 |
| Change From Baseline at Week 4 | -0.25 ± 0.50 | -2.58 ± 0.34 | -3.10 ± 0.33 |
| Change From Baseline at Week 8 | -0.43 ± 0.59 | -2.97 ± 0.39 | -3.62 ± 0.39 |
The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.
| score on a scale | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Change From Baseline at Week 2 | -0.58 ± 0.49 | -1.76 ± 0.33 | -2.25 ± 0.33 |
| Change From Baseline at Week 4 | -1.06 ± 0.55 | -2.71 ± 0.37 | -2.97 ± 0.36 |
| Change From Baseline at Week 8 | -1.22 ± 0.62 | -3.34 ± 0.41 | -3.52 ± 0.40 |
The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.
| score on a scale | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Change From Baseline at Week 12 | -1.51 ± 4.739 | -2.22 ± 7.305 | -0.39 ± 3.984 | -0.39 ± 3.907 |
| Change From Baseline at Week 24 | -0.54 ± 5.211 | -2.66 ± 7.268 | 0.11 ± 4.929 | 0.02 ± 5.584 |
| Change From Baseline at Week 52 | -0.97 ± 5.085 | -2.81 ± 7.005 | -0.37 ± 5.775 | -0.54 ± 5.511 |
The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.
| score on a scale | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Change From Baseline at Week 12 | -1.93 ± 5.284 | -2.67 ± 7.160 | -0.67 ± 4.575 | -0.66 ± 3.865 |
| Change From Baseline at Week 24 | -1.22 ± 5.681 | -3.15 ± 8.242 | 0.02 ± 5.536 | 0.51 ± 5.563 |
| Change From Baseline at Week 52 | -1.95 ± 4.876 | -3.31 ± 7.082 | -0.27 ± 6.506 | -0.07 ± 5.918 |
Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Used the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.
| % BSA | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Change From Baseline at Week 2 | -0.43 ± 5.559 | -3.69 ± 4.230 | -3.76 ± 4.238 |
| Change From Baseline at Week 4 | -1.56 ± 4.088 | -5.29 ± 4.969 | -5.25 ± 5.190 |
| Change From Baseline at Week 8 | -2.51 ± 4.722 | -6.30 ± 5.378 | -6.54 ± 4.967 |
Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Used the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.
| % BSA | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Change From Baseline at Week 12 | -4.23 ± 4.849 | -2.84 ± 4.907 | -6.84 ± 4.852 | -6.96 ± 4.989 |
| Change From Baseline at Week 16 | -4.96 ± 5.194 | -2.98 ± 5.429 | -7.36 ± 4.875 | -7.26 ± 5.080 |
| Change From Baseline at Week 20 | -4.78 ± 5.095 | -3.75 ± 5.321 | -7.69 ± 4.901 | -7.49 ± 5.012 |
| Change From Baseline at Week 24 | -5.32 ± 4.964 | -3.85 ± 5.223 | -7.64 ± 4.998 | -7.64 ± 4.737 |
| Change From Baseline at Week 28 | -4.56 ± 5.486 | -4.43 ± 4.995 | -7.66 ± 5.029 | -7.62 ± 4.913 |
| Change From Baseline at Week 32 | -5.17 ± 4.472 | -4.53 ± 5.399 | -7.80 ± 5.011 | -7.61 ± 5.261 |
| Change From Baseline at Week 36 | -5.21 ± 4.972 | -4.39 ± 5.509 | -8.18 ± 5.111 | -7.97 ± 5.010 |
| Change From Baseline at Week 40 | -4.67 ± 5.519 | -4.75 ± 5.337 | -8.07 ± 4.899 | -8.11 ± 4.997 |
| Change From Baseline at Week 44 | -5.28 ± 5.173 | -4.56 ± 5.609 | -8.14 ± 4.789 | -8.02 ± 4.939 |
| Change From Baseline at Week 48 | -5.65 ± 5.128 | -4.58 ± 5.696 | -8.39 ± 5.023 | -7.96 ± 4.993 |
| Change From Baseline at Week 52 | -5.72 ± 5.481 | -4.93 ± 5.771 | -8.58 ± 5.013 | -8.14 ± 4.906 |
The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (clear or almost clear) to 28 (very severe eczema). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.
| score on a scale | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Change From Baseline at Week 2 | -2.25 ± 5.779 | -9.47 ± 7.212 | -10.60 ± 6.670 |
| Change From Baseline at Week 4 | -3.38 ± 6.685 | -10.12 ± 7.380 | -11.53 ± 6.891 |
| Change From Baseline at Week 8 | -4.30 ± 7.044 | -10.60 ± 7.262 | -11.82 ± 6.931 |
The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.
| score on a scale | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Change From Baseline at Week 12 | -5.95 ± 6.607 | -6.89 ± 9.730 | -10.74 ± 6.653 | -11.38 ± 6.710 |
| Change From Baseline at Week 24 | -4.46 ± 6.185 | -7.26 ± 9.189 | -10.46 ± 6.655 | -11.44 ± 6.689 |
| Change From Baseline at Week 52 | -4.61 ± 6.868 | -7.00 ± 8.752 | -10.51 ± 7.396 | -10.61 ± 7.057 |
The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.
| score on a scale | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Change From Baseline at Week 2 | -1.54 ± 4.618 | -6.18 ± 5.740 | -6.90 ± 5.980 |
| Change From Baseline at Week 4 | -2.50 ± 6.101 | -6.88 ± 5.867 | -7.15 ± 6.565 |
| Change From Baseline at Week 8 | -2.83 ± 6.722 | -7.28 ± 5.907 | -7.72 ± 6.152 |
The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.
| score on a scale | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Change From Baseline at Week 12 | -3.65 ± 5.602 | -4.53 ± 6.246 | -7.67 ± 5.855 | -7.79 ± 6.240 |
| Change From Baseline at Week 24 | -3.21 ± 4.814 | -5.32 ± 6.304 | -7.87 ± 6.080 | -7.75 ± 6.277 |
| Change From Baseline at Week 52 | -3.35 ± 5.438 | -4.81 ± 6.720 | -7.95 ± 6.589 | -7.70 ± 6.443 |
CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.
| score on a scale | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Change From Baseline at Week 2 | -1.06 ± 3.733 | -5.06 ± 6.937 | -6.76 ± 6.306 |
| Change From Baseline at Week 4 | -2.47 ± 6.530 | -4.35 ± 8.683 | -6.90 ± 5.101 |
| Change From Baseline at Week 8 | -2.31 ± 5.618 | -5.88 ± 7.524 | -7.61 ± 6.142 |
CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.
| score on a scale | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Change From Baseline at Week 12 | -4.00 ± 5.477 | -1.13 ± 8.097 | -5.83 ± 7.661 | -8.86 ± 5.532 |
| Change From Baseline at Week 24 | -2.71 ± 5.155 | -2.00 ± 3.780 | -6.72 ± 7.640 | -9.42 ± 7.214 |
| Change From Baseline at Week 52 | -4.33 ± 8.359 | -0.43 ± 4.928 | -6.70 ± 7.766 | -9.71 ± 6.262 |
The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.
| score on a scale | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Week 2 | 3.53 ± 1.500 | 2.06 ± 0.937 | 1.94 ± 0.911 |
| Week 4 | 3.30 ± 1.434 | 1.78 ± 0.903 | 1.68 ± 0.843 |
| Week 8 | 3.08 ± 1.489 | 1.76 ± 0.913 | 1.61 ± 0.914 |
The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Week 2 - Very Much Improved: 1 | 5.3 | 31.4 | 36.7 |
| Week 2 - Much Improved: 2 | 18.6 | 38.6 | 40.1 |
| Week 2 - Minimally Improved: 3 | 37.2 | 25.0 | 16.9 |
| Week 2 - No Change: 4 | 13.3 | 4.2 | 5.5 |
| Week 2 - Minimally Worse: 5 | 11.5 | 0.4 | 0.8 |
| Week 2 - Much Worse: 6 | 10.6 | 0.0 | 0.0 |
| Week 2 - Very Much Worse: 7 | 3.5 | 0.4 | 0.0 |
| Week 4 - Very Much Improved: 1 | 6.7 | 48.5 | 51.7 |
| Week 4 - Much Improved: 2 | 22.9 | 29.5 | 32.1 |
| Week 4 - Minimally Improved: 3 | 38.1 | 18.1 | 13.3 |
| Week 4 - No Change: 4 | 11.4 | 3.0 | 2.1 |
| Week 4 - Minimally Worse: 5 | 11.4 | 0.8 | 0.8 |
| Week 4 - Much Worse: 6 | 6.7 | 0.0 | 0.0 |
| Week 4 - Very Much Worse: 7 | 2.9 | 0.0 | 0.0 |
| Week 8 - Very Much Improved: 1 | 11.0 | 48.4 | 59.8 |
| Week 8 - Much Improved: 2 | 30.0 | 33.2 | 25.8 |
| Week 8 - Minimally Improved: 3 | 29.0 | 14.8 | 10.0 |
| Week 8 - No Change: 4 | 12.0 | 1.3 | 2.2 |
| Week 8 - Minimally Worse: 5 | 7.0 | 2.2 | 2.2 |
| Week 8 - Much Worse: 6 | 10.0 | 0.0 | 0.0 |
| Week 8 - Very Much Worse: 7 | 1.0 | 0.0 | 0.0 |
The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.
| percentage of participants | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Week 2 | 23.9 (16.4 to 32.8) | 69.9 (63.6 to 75.7) | 76.8 (70.9 to 82.0) |
| Week 4 | 29.5 (21.0 to 39.2) | 78.1 (72.2 to 83.2) | 83.8 (78.5 to 88.2) |
| Week 8 | 41.0 (31.3 to 51.3) | 81.6 (75.9 to 86.5) | 85.6 (80.4 to 89.9) |
EQ-5D-5L questionnaire has 2 parts: EQ-5D-5L descriptive system \& EQ-VAS. EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 5L indicates that for each dimension, there are 5 levels:1=no problems,2=slight problems,3=moderate problems,4=severe problems, and 5=extreme problems. EQ-5D-5L score is assessed using VAS that ranges from 0 to 100 millimetres (mm), where 0 indicates "worst health you can imagine" and 100 indicates "best health you can imagine". The participant was asked to indicate his/her health state over past 7 days in each of the 5 dimensions. Digits for the 5 dimensions can be combined into a 5-digit number that describes the participant's health state. In the EQ-VAS, participants had to record their health state on a scale ranging from 0 to 100. A positive change from Baseline indicates improvement.
| score on a scale | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Change From Baseline at Week 2 | -0.94 ± 14.046 | 6.93 ± 17.690 | 8.21 ± 15.770 |
| Change From Baseline at Week 4 | 1.76 ± 11.618 | 8.73 ± 17.494 | 7.10 ± 16.697 |
| Change From Baseline at Week 8 | 1.74 ± 14.376 | 9.12 ± 17.871 | 7.98 ± 16.813 |
The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.
| score on a scale | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Percent Work Time Missed Due to AD: Change From Baseline at Week 2 | 4.45 ± 19.542 | -3.89 ± 24.223 | 1.19 ± 14.954 |
| Percent Work Time Missed Due to AD: Change From Baseline at Week 4 | 14.09 ± 30.660 | 1.22 ± 23.898 | 3.43 ± 17.242 |
| Percent Work Time Missed Due to AD: Change From Baseline at Week 8 | 5.07 ± 23.253 | -0.26 ± 23.891 | 6.23 ± 22.211 |
| Percent Impairment While Working Due to AD: Change From Baseline at Week 2 | -7.36 ± 22.630 | -15.00 ± 22.494 | -16.75 ± 20.951 |
| Percent Impairment While Working Due to AD: Change From Baseline at Week 4 | -9.56 ± 25.580 | -16.86 ± 22.417 | -19.43 ± 20.933 |
| Percent Impairment While Working Due to AD: Change From Baseline at Week 8 | -13.54 ± 28.019 | -19.43 ± 24.878 | -21.61 ± 22.071 |
| Percent Overall Work Impairment Due to AD: Change From Baseline at Week 2 | -5.27 ± 21.539 | -15.04 ± 27.812 | -15.49 ± 23.785 |
| Percent Overall Work Impairment Due to AD: Change From Baseline at Week 4 | -2.35 ± 27.602 | -13.82 ± 26.207 | -15.82 ± 25.545 |
| Percent Overall Work Impairment Due to AD: Change From Baseline at Week 8 | -9.01 ± 31.735 | -18.09 ± 27.718 | -15.54 ± 27.119 |
| Percent Activity Impairment Due to AD: Change From Baseline at Week 2 | -6.32 ± 23.434 | -16.58 ± 24.696 | -21.56 ± 24.695 |
| Percent Activity Impairment Due to AD: Change From Baseline at Week 4 | -10.09 ± 26.349 | -20.80 ± 24.107 | -23.53 ± 25.422 |
| Percent Activity Impairment Due to AD: Change From Baseline at Week 8 | -11.70 ± 28.992 | -21.30 ± 24.653 | -24.06 ± 26.682 |
The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.
| score on a scale | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12 | -4.78 ± 18.023 | -2.02 ± 4.902 | -0.26 ± 27.118 | 7.72 ± 22.067 |
| Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24 | -0.39 ± 21.466 | 4.77 ± 16.899 | -1.00 ± 28.511 | 4.96 ± 18.942 |
| Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36 | -3.92 ± 23.687 | -3.12 ± 6.143 | -0.32 ± 27.115 | 8.93 ± 21.916 |
| Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52 | -8.11 ± 18.718 | 3.23 ± 26.008 | 1.81 ± 26.094 | 2.38 ± 16.245 |
| Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12 | -11.50 ± 23.458 | -18.64 ± 28.668 | -20.21 ± 24.925 | -20.65 ± 21.844 |
| Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24 | -8.42 ± 16.754 | -16.67 ± 28.697 | -23.51 ± 25.067 | -23.66 ± 24.396 |
| Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36 | -3.13 ± 20.887 | -8.46 ± 33.378 | -23.15 ± 25.813 | -22.72 ± 23.185 |
| Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52 | -10.00 ± 25.166 | -20.00 ± 27.634 | -23.42 ± 26.597 | -22.77 ± 24.109 |
| Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12 | -12.18 ± 24.763 | -19.64 ± 28.842 | -18.21 ± 28.345 | -14.99 ± 28.777 |
| Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24 | -7.46 ± 16.254 | -12.96 ± 34.336 | -20.26 ± 31.191 | -18.60 ± 28.284 |
| Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36 | -5.70 ± 23.040 | -10.43 ± 33.034 | -20.52 ± 31.307 | -14.86 ± 29.482 |
| Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52 | -16.36 ± 29.721 | -16.67 ± 40.350 | -19.42 ± 29.878 | -20.50 ± 26.949 |
| Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12 | -12.20 ± 21.273 | -8.48 ± 26.244 | -21.50 ± 26.470 | -25.19 ± 26.314 |
| Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24 | -11.46 ± 16.517 | -7.14 ± 25.113 | -22.83 ± 27.440 | -27.47 ± 25.943 |
| Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36 | -6.39 ± 18.997 | -1.25 ± 27.845 | -24.48 ± 26.203 | -26.84 ± 27.493 |
| Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52 | -11.05 ± 24.910 | -13.42 ± 25.392 | -22.91 ± 27.669 | -26.92 ± 28.042 |
Plasma samples were collected just before the morning application of study drug during each specified time point.
| nanomole per liter (nM) | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Week 2 | 26.8 ± 51.2 | 33.4 ± 49.9 |
| Week 4 | 25.1 ± 42.7 | 34.7 ± 43.3 |
| Week 8 | 24.0 ± 39.7 | 33.3 ± 49.5 |
Plasma samples were collected just before the morning application of study drug during each specified time point.
| nM | LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID | LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID | LTS Period: Ruxolitinib 0.75% Cream | LTS Period: Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Week 12 | 13.8 ± 21.3 | 21.9 ± 34.4 | 16.5 ± 28.1 | 24.9 ± 45.4 |
| Week 16 | 11.9 ± 18.8 | 18.1 ± 34.6 | 19.7 ± 58.8 | 24.6 ± 51.0 |
| Week 20 | 13.0 ± 22.2 | 15.4 ± 32.0 | 16.1 ± 31.2 | 24.2 ± 46.1 |
| Week 24 | 13.0 ± 22.1 | 18.7 ± 31.6 | 18.8 ± 42.4 | 24.6 ± 51.8 |
| Week 28 | 18.5 ± 36.9 | 15.5 ± 24.6 | 16.2 ± 31.2 | 23.7 ± 45.3 |
| Week 32 | 17.8 ± 27.3 | 17.7 ± 33.3 | 21.4 ± 59.8 | 21.0 ± 35.3 |
| Week 36 | 21.1 ± 54.8 | 29.5 ± 84.0 | 15.7 ± 30.5 | 26.6 ± 51.2 |
| Week 40 | 14.9 ± 25.3 | 16.5 ± 31.0 | 14.7 ± 27.6 | 23.2 ± 64.1 |
| Week 44 | 14.3 ± 23.7 | 15.7 ± 32.6 | 17.3 ± 33.5 | 26.8 ± 58.6 |
| Week 48 | 15.6 ± 26.8 | 17.9 ± 56.0 | 15.3 ± 30.3 | 24.8 ± 55.3 |
| Week 52 | 11.0 ± 17.9 | 14.2 ± 27.5 | 11.9 ± 20.5 | 21.0 ± 55.7 |
Collected over Up to 60 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle Cream BID | 0/126 (0%) | 2/126 (1.6%) | 10/126 (7.9%) |
| Ruxolitinib 0.75% Cream BID | 0/300 (0%) | 9/300 (3%) | 52/300 (17.3%) |
| Ruxolitinib 1.5% Cream BID | 0/300 (0%) | 6/300 (2%) | 70/300 (23.3%) |
| Event | Vehicle Cream BID | Ruxolitinib 0.75% Cream BID | Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 1/126 | 0/300 | 0/300 |
| Nasal sinus cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/126 | 0/300 | 0/300 |
| PneumoniaInfections and infestations | 0/126 | 2/300 | 1/300 |
| Acute abdomenGastrointestinal disorders | 0/126 | 0/300 | 1/300 |
| ColitisGastrointestinal disorders | 0/126 | 0/300 | 1/300 |
| Anaemia postoperativeInjury, poisoning and procedural complications | 0/126 | 1/300 | 0/300 |
| Femur fractureInjury, poisoning and procedural complications | 0/126 | 1/300 | 0/300 |
| Humerus fractureInjury, poisoning and procedural complications | 0/126 | 1/300 | 0/300 |
| Pelvic fractureInjury, poisoning and procedural complications | 0/126 | 1/300 | 0/300 |
| Radius fractureInjury, poisoning and procedural complications | 0/126 | 1/300 | 0/300 |
| Event | Vehicle Cream BID | Ruxolitinib 0.75% Cream BID | Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/126 | 27/300 | 36/300 |
| NasopharyngitisInfections and infestations | 2/126 | 18/300 | 31/300 |
| HeadacheNervous system disorders | 5/126 | 11/300 | 16/300 |
Intent-to-treat (ITT) population included all participants who were randomized to the study.
| Age, Continuous(years) | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|---|
| Mean | 35.2 ± 18.11 | 36.8 ± 19.06 | 33.7 ± 17.15 | 35.2 ± 18.15 |
| Sex: Female, Male(Participants) | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|---|
| Female | 79 | 154 | 158 | 391 |
| Male | 47 | 98 | 95 | 240 |
| Ethnicity (NIH/OMB)(Participants) | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|---|
| Hispanic or Latino | 21 | 30 | 37 | 88 |
| Not Hispanic or Latino | 104 | 218 | 212 | 534 |
| Unknown or Not Reported | 1 | 4 | 4 | 9 |
| Race/Ethnicity, Customized(Participants) | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 0 | 2 |
| Asian | 8 | 10 | 14 | 32 |
| Native Hawaiian or Other Pacific Islander | 0 | 3 | 0 | 3 |
| Black or African American | 29 | 55 | 56 | 140 |
| White | 85 | 173 | 177 | 435 |
| Other | 4 | 9 | 6 | 19 |
| Body Mass Index (BMI)(Kilograms per square metre (kg/m^2)) | VC Period: Vehicle Cream BID | VC Period: Ruxolitinib 0.75% Cream BID | VC Period: Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|---|
| Mean | 26.92 ± 6.245 | 27.33 ± 6.745 | 27.47 ± 8.077 | 27.30 ± 7.212 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in Dec 2019, 12 months.
Results were first posted in Dec 2021, 1 year 11 months after primary completion. A results delay was requested in Dec 2020.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 12 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib